• posted by: Lee Smith
• posted on: August 17, 2021

Conducting well-designed structured studies is important when formulating any vaccine. For live viral vaccines, some challenges include limited analytical tools and inherent variability that make evaluation difficult.

• posted by: Lee Smith
• posted on: March 30, 2020

Animated bubble plot of cumulative COVID-19 cases & deaths by country.

• posted by: Lee Smith
• posted on: January 19, 2020

Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe. We focus here on two live attenuated viral vaccines that have quite different profiles; the first, dengue, a disease where no vaccine exists and the second, influenza, a disease for which there have been a number of vaccines available over the decades yet none that are universal.

• posted by: Lee Smith
• posted on: November 4, 2019

A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials. The clinical studies were performed at Imperial College London and demonstrated the safety of the vaccine.

• posted by: Lee Smith
• posted on: July 24, 2019

Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy. Unlike traditional treatments which seek to treat or manage diseases, or disorders by introducing agents outside the body, gene therapy uses the body itself to fight off such conditions.

• posted by: Lee Smith
• posted on: June 5, 2019

CEPI awards US$21 million to Themis Bioscience

• posted by: Lee Smith
• posted on: February 25, 2019

Chikungunya Vaccine receives FDA Fast Track Designation

• posted by: Lee Smith
• posted on: February 13, 2019

FluGen’s Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial

• posted by: Lee Smith
• posted on: January 30, 2019

Takeda Vaccine's Dengue Vaccine meets its Primary Endpoints in Phase III Efficacy Trial.